

Tildren®

(tiludronate disodium)

BISPHOSPHONATE DRUG FOR INTRAVENOUS INFUSION

FOR USE IN HORSES ONLY

NADA 141-420, Approved By FDA

CAUTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS

Tildren® is indicated for the control of clinical signs associated with navicular syndrome in horses.

Navicular syndrome is the most common cause of chronic forelimb lameness in performance horses. It is a degenerative process instigated by mechanical forces.

BENEFITS

- Restores balance to the process of bone remodeling
- Decreases mineral loss and slows the rate of bone turnover
- Alleviates pain induced by abnormal osteolysis



PACKAGING

LIST NO.	UNIT PACKAGE	CASE SIZE
1TIL004	500 mg	12

WARNINGS

Do not use in horses intended for human consumption. NSAIDs should not be used concurrently with Tildren®. Concurrent use of NSAIDs with Tildren® may increase the risk of renal toxicity and acute renal failure.

HUMAN WARNINGS

Not for use in humans. Keep this and all drugs out of the reach of children. Consult a physician in case of accidental human exposure.

Bimeda, Inc.
One Tower Lane, Suite 2250
Oakbrook Terrace, IL 60181 USA
Toll Free Tel. 888-524-6332 • Toll Free Fax. 877-888-7035
Email: Info@BimedaUS.com, EquineInfo@BimedaUS.com

See reverse side for additional information



www.BimedaUS.com
www.BimedaEquine.com